Project Grant R01HL173055
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$835K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $347,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma by Biotherapeutics, Inc., an emerging biotechnology company. The goal is to characterize the therapeutic efficacy and administration route of the drug candidate in mouse models of asthma, and determine its translational potential...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $355,935 to Biotherapeutics, Inc., a biotechnology company located in Blacksburg, Virginia. The grant funding supports the development of a novel, oral immunoregulatory therapeutic for treating asthma. The key objectives are to characterize the therapeutic efficacy and optimal route of administration in mouse models of asthma, and...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to integrate multi-omics data and understand the heterogeneity and endotypes of asthma. The $177,403 award, effective September 1, 2024 through August 31, 2029, will enable the Brigham & Women's Hospital Inc. to analyze the interplay between genetic, epigenetic, and metabolomic factors in asthma...
This federal Project Grant award of $249,000.00 from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop methodologies to reveal the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund the creation of a strain-resolved computational pipeline for reduced metagenomic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will support research to characterize the role of lung stromal factors in modulating the inflammatory response and tissue-resident lymphocyte accumulation in asthmatic airways. The $636,843 award to the Regents of the University of California, San Francisco will utilize novel genetic tools, human organoid platforms, and a proprietary...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $715,968 to Brigham & Women's Hospital Inc. to conduct research on the mechanisms underlying mast cell expansion and function in human airway diseases. The key objectives of this 5-year project are to: 1) evaluate the concentration of mast cell progenitors in human sinus tissue across different disease endotypes, 2) test the...
The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research federal grant program (CFDA 93.837), has awarded a $790,698 Project Grant to The University of Texas Southwestern Medical Center. The grant will fund a single-site, 24-week, randomized, double-blind, placebo-controlled clinical trial to examine the efficacy of the selective serotonin reuptake inhibitor (SSRI) escitalopram in improving asthma control and reducing exacerbations in adults with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., an emerging biotechnology company in Blacksburg, Virginia, to develop a novel oral immunoregulatory therapeutic for the treatment of asthma. The specific aims of this research are to: 1) Determine the safety profile and pharmacokinetics of the new immunoregulatory therapeutic through oral...
This federal Project Grant award of $387,116 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to define the neural mechanisms triggered by house dust mite (HDM) exposure that lead to the development of airway hyperreactivity (AHR) in asthma. The research seeks to identify the specific nerve subtypes and signaling pathways involved in HDM-induced AHR, in order to develop targeted therapies. Specifically, the study...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,806 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Elimu Informatics Inc., a small business software company in California. The grant funds the development of TIBSA (Tailored Interoperable Guideline-Based Clinical Decision-Support System for Asthma), a software application that will incorporate the updated 2020 NHLBI asthma management guidelines, patient-specific clinical data, shared...